MedTrace Logo

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-08-26

No results posted yet for this study

Summary

Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.

Conditions

  • Aspirin-exacerbated Respiratory Disease

Interventions

DRUG

Dupilumab

dupilumab 300 mg subcutaneous injection every 2 weeks

Sponsors & Collaborators

  • Rochester General Hospital

    lead OTHER

Principal Investigators

  • S Shahzad Mustafa, MD · Lead Physician

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2019-12-11
Completion
2019-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595488 on ClinicalTrials.gov